Key result
ABEI-based CA125 assay shows ~0.97 correlation with Cobas e602, linking elevated levels to CV mortality.
Why the study?
CA125 is increasingly recognized as a marker of congestion and inflammation in heart failure, but its analytical performance and relationship with remodeling biomarkers in HFrEF require evaluation.
Observational (n=108)
ABEI-based CA125 measurement shows comparable analytical performance to established assays and significantly correlates with clinical severity, remodeling biomarkers, and cardiovascular mortality in HFrEF.
Answers are grounded in this paper and cite their sources.
May enable wider CA125 testing in HF labs; leaves open its added value for remodeling assessment beyond NT-proBNP.
Carbohydrate antigen 125 (CA125), which is traditionally used in ovarian cancer diagnostics, is increasingly recognized as a marker of congestion and inflammation in heart failure (HF). This study compared the analytical performance of N-(4-aminobutyl)-N-ethylisoluminol (ABEI)-based CA125 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) assays on the Maglumi® X6 analyzer with that of the Roche Cobas e602 system and explored the relationship of CA125 with biomarkers of adverse remodeling in HF with reduced ejection fraction (HFrEF). Imprecision testing and method comparison were performed on matched serum samples from 108 HFrEF patients. CA125 concentrations were evaluated in relation to the New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), galectin-3, and soluble suppression of tumorigenicity 2 (sST2) levels. Prognostic value was assessed by Kaplan-Meier survival analysis using the 35 U/mL threshold. The ABEI based CA125 assay showed low imprecision [coefficient of variation (CV)≤4.5%] and strong agreement with the Cobas e602 assay ( R =0.97, slope=1.06, P <0.001). CA125 levels increased progressively with NYHA class ( P =0.02), correlated negatively with LVEF ( R =–0.38, P <0.001) and positively with galectin-3 ( R =0.21, P =0.03) and sST2 ( R =0.57, P <0.001). Elevated CA125 levels (≥35 U/mL) were associated with significantly increased cardiovascular mortality ( P <0.001). ABEI-based CA125 measurement provides an analytical performance comparable to that of Cobas e602. In HFrEF, CA125 is correlated with clinical severity, fibrosis/inflammation biomarkers, and prognosis. Its integration into multimarker strategies, particularly alongside NT-proBNP and sST2, may enhance risk stratification and therapeutic monitoring, including the response to sodium–glucose cotransporter-2 (SGLT2) inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Ali Khatib (2025) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=108). ABEI-based CA125 immunoassay vs. Roche Cobas e602 system was evaluated on Method comparison between ABEI-based CA125 and Cobas e602 assays (R=0.97, p=<0.001). The ABEI-based CA125 assay showed strong analytical agreement with the Cobas e602 assay (R=0.97, P<0.001), and elevated CA125 (≥35 U/mL) was associated with increased cardiovascular mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: